Abstract
T-large granular lymphocytic leukemia (T-LGLL) is a rare T lymphocyte proliferative disease, and its clinical manifestations are splenomegaly, neutropenia and autoimmune diseases such as rheumatoid arthritis (RA). The pathogenesis of T-LGLL is to activate survival signaling pathway and inhibit apoptotic signaling pathway to maintain long-term activation of large granular lymphocytes (LGL) by chronic antigenic stimulation. Traditional treatment methods of T-LGLL are mainly immune inhibitors such as methotrexate, cyclophosphamide and other drugs, but now there are some new drugs such as tofacitinib in clinical research. Now, the clinical research progress of T-LGLL is reviewed. Key words: Leukemia, large granular lymphocytic; Etiology; Immunosuppressive agents
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
